Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Pipeline Monitor
Expanded US use for Xarelto
While AZ's Lynparza gets fourth orphan nod.
Perspective
The pitfalls of political hype
Surprise! Your new drug is now a miracle cure.
Approvals Action
More generics added
Alphapharm and Boucher & Muir drugs approved.